Researchers at the Universitat de Barcelona have successfully developed a new compound capable of reversing cognitive decline in Alzheimer’s disease within animal models. The team from the Institute of Neurosciences validated the experimental drug FLAV-27 using a novel epigenetic mechanism distinct from current market treatments. Published in Molecular Therapy, this study suggests a viable pathway for disease modification rather than mere symptom management.
Current approved therapies primarily target beta-amyloid protein accumulation through monoclonal antibodies like lecanemab and donanemab. These existing treatments slow cognitive decline by approximately 30% but fail to address underlying molecular drivers effectively. In contrast, FLAV-27 inhibits the G9a enzyme, which regulates gene expression essential for neuronal development and memory consolidation.
The compound functions by preventing access to S-adenosylmethionine, a specific molecule required for the enzyme to modify DNA sequences. Researchers state this inhibition slows epigenetic dysregulation characteristic of the disease progression significantly. Consequently, neurons regain normal function while classic pathological markers decrease significantly in treated subjects.
Functional recovery extends beyond molecular changes to restored social behavior and synaptic structure across multiple biological models. Tests included in vitro assays and murine models representing both early-onset and late-onset forms of the condition. Data indicates improved short-term and long-term memory alongside enhanced spatial navigation capabilities in the study group.
A key differentiator involves the identification of biomarkers measurable in blood plasma to monitor treatment efficacy accurately. Indicators such as H3K9me2 and p-tau181 return to normal levels parallel with cognitive recovery in test subjects. This peripheral bioindicator availability simplifies future clinical trial patient selection and ongoing monitoring processes considerably.
Commercial development will proceed through Flavii Therapeutics, a spin-off established by the university in 2025 specifically for this technology. The company holds exclusive licensing rights for the compound and manages associated intellectual property and fundraising. Efforts aim to convert academic knowledge into accessible therapies for central nervous system diseases globally.
Advancing to human trials requires completion of regulatory toxicology studies in at least two different animal species prior to advancement. The pharmaceutical form must be finalized before applying for authorization from relevant global health agencies. This transition phase represents a critical hurdle that typically spans several years of rigorous development.
The initiative involves collaboration with numerous international centers including prestigious institutions in the United Kingdom and Mexico. Partners range from the University College London to the Medical Campus of the University of Colorado Anschutz. Such global cooperation underscores the distributed nature of modern biomedical research infrastructure and funding.
Success of this approach could establish a new category of epigenetic disease-modifying therapies for neurodegenerative conditions. These treatments might eventually complement or replace strategies based exclusively on amyloid elimination in clinical settings. Market analysts anticipate significant investment interest if safety profiles match preclinical efficacy data observed.
Stakeholders will monitor the progress of Flavii Therapeutics as it navigates the complex preclinical phase ahead of regulatory submission. Regulatory agencies will assess whether the drug meets standards for approval in human populations over the coming years. The outcome could define the next decade of Alzheimer’s treatment strategies globally and reshape the healthcare sector significantly.
